Mastodon

Aldospray (Aerosol) Instructions for Use

Marketing Authorization Holder

Aldo-Union, S.A. (Spain)

ATC Code

M02AA (Topical non-steroidal anti-inflammatory drugs)

Active Substance

Mabuprofen (Rec.INN registered by WHO)

Dosage Form

Bottle OTC Icon Aldospray Aerosol for external use 10%: canister 90 g

Dosage Form, Packaging, and Composition

Aerosol for external use 10% in the form of a homogeneous foamy mass of white color.

1 g
Mabuprofen 100 mg

Excipients: dimethyl sulfoxide, cetyl alcohol, Siegert L-2-SM esterin, polyethylene 23 lauryl ether, sorbitan monostearate, sorbitan monooleate, triethanolamine, propylene glycol, povidone, benzyl alcohol, 1,1,1,2-tetrafluoroethane (propellant 134a), purified water.

90 g – aluminum canisters (1) with a polypropylene sprayer and a cap – cardboard packs.

Clinical-Pharmacological Group

NSAIDs for external use

Pharmacotherapeutic Group

NSAID

Pharmacological Action

NSAID for external use, an ibuprofen derivative. It has a pronounced anti-inflammatory and analgesic effect. The mechanism of action is associated with inhibition of prostaglandin synthesis due to non-selective blockade of COX1 and COX2.

Pharmacokinetics

When applied externally, Mabuprofen is absorbed and undergoes hydrolysis, resulting in the release of ibuprofen. Systemic bioavailability is up to 18%.

The binding of ibuprofen to plasma proteins is 90%. During biotransformation, 4 metabolites are formed: 2-p-(2-hydroxy-2-methylpropyl) phenylpropionic acid, 2-p-(carboxypropyl) phenylpropionic acid), 2-4-(2-hydroxymethylpropyl) phenylpropionic acid, 2-4-(1-hydroxy-2-methylpropyl) phenylpropionic acid.

Up to 60% is excreted by the kidneys: about 9% as oxidized metabolites, up to 17% as conjugated oxidized metabolites, 16% as carboxylated metabolites, 19% as conjugated carboxylated metabolites.

Indications

Inflammatory and degenerative diseases of the musculoskeletal system (including rheumatoid arthritis in remission stage, arthralgia in rheumatism, gout /as part of complex therapy/, psoriatic arthritis, shoulder periarthritis, ankylosing spondylitis, deforming osteoarthritis, osteochondrosis with radicular syndrome, radiculitis, sciatic nerve neuritis, tendonitis, tenosynovitis, bursitis, low back pain).

Injuries (including sports, occupational, domestic) without violation of the integrity of soft tissues (including dislocations, sprains or ruptures of muscles and ligaments, contusions, post-traumatic soft tissue edema).

Pain syndrome of various origins (postoperative pain, neuralgia, tendonitis, bursitis, radiculitis, traumatic inflammation of soft tissues and the musculoskeletal system).

Myalgia of various origins.

Superficial phlebitis, periphlebitis (as part of combination therapy).

ICD codes

ICD-10 code Indication
I80 Phlebitis and thrombophlebitis
M05 Seropositive rheumatoid arthritis
M07 Psoriatic and enteropathic arthropathies
M10 Gout
M13.9 Arthritis, unspecified
M15 Polyosteoarthritis
M19.9 Unspecified arthrosis
M25.5 Pain in joint
M42 Spinal osteochondrosis
M45 Ankylosing spondylitis
M47 Spondylosis
M54.1 Radiculopathy
M54.3 Sciatica
M54.4 Lumbago with sciatica
M65 Synovitis and tenosynovitis
M70 Soft tissue disorders related to use, overuse, and pressure
M71 Other bursopathies
M75.0 Adhesive capsulitis of shoulder
M79.1 Myalgia
M79.2 Neuralgia and neuritis, unspecified
R52.0 Acute pain
R52.2 Other chronic pain
T14.0 Superficial injury of unspecified body region (including abrasion, bruise, contusion, hematoma, bite of nonvenomous insect)
T14.3 Dislocation, sprain and strain of joint and ligament of unspecified body region
ICD-11 code Indication
8B93.Z Radiculopathy, unspecified
8E4A.1 Paraneoplastic or autoimmune diseases of the peripheral or autonomic nervous system
BD70.0 Superficial thrombophlebitis of lower extremities
BD70.Z Superficial thrombophlebitis, unspecified
BD71.4 Deep vein thrombosis of lower extremity
BD7Z Diseases of veins, unspecified
EH92 Dermatoses provoked by friction or mechanical impact
EH92.1 Blister due to friction
FA05 Polyosteoarthritis
FA0Z Osteoarthritis, unspecified
FA20.0 Seropositive rheumatoid arthritis
FA21.Z Psoriatic arthritis, unspecified
FA25 Gout
FA2Z Inflammatory arthropathies, unspecified
FA85.Z Defects of vertebral end-plates, unspecified
FA8Z Degenerative disease of spine, unspecified
FA92.0Z Ankylosing spondylitis, unspecified
FB40.Z Tenosynovitis, unspecified
FB50.1 Bursitis associated with use, overuse or pressure
FB50.Z Bursitis, unspecified
FB53.0 Adhesive capsulitis of shoulder
FB56 Specified soft tissue diseases, not elsewhere classified
FB56.2 Myalgia
ME82 Pain in joint
ME84.20 Lumbago with sciatica
ME84.3 Sciatica
MG30.Z Chronic pain syndrome, unspecified
MG31.Z Acute pain, unspecified
ND56.0 Superficial injury of unspecified body region
ND56.3 Dislocation, sprain or strain of unspecified body region

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

For external use only. Apply the aerosol to intact skin over the painful area.

Shake the canister vigorously immediately before each use.

Hold the canister upright and spray from a distance of approximately 10-15 cm (4-6 inches).

Apply a sufficient amount to cover the entire affected area with a thin, uniform layer.

Administer the spray two to three times daily. The interval between applications should be at least four hours.

Gently massage the foam into the skin until fully absorbed.

Wash hands thoroughly with soap and water after application, unless the hands are the treated area.

The duration of continuous use should not exceed ten days for analgesia or fourteen days for anti-inflammatory effect without medical consultation.

Discontinue use and consult a physician if symptoms persist or worsen.

Avoid covering the treated area with occlusive dressings or tight bandages unless directed by a physician.

Adverse Reactions

Rarely erythema, burning sensation at the application site.

Contraindications

Hypersensitivity to mabuprofen.

Special Precautions

During application, avoid contact of the active substance with open wound surfaces and mucous membranes.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

TABLE OF CONTENTS